JP2002533125A5 - - Google Patents

Download PDF

Info

Publication number
JP2002533125A5
JP2002533125A5 JP2000591194A JP2000591194A JP2002533125A5 JP 2002533125 A5 JP2002533125 A5 JP 2002533125A5 JP 2000591194 A JP2000591194 A JP 2000591194A JP 2000591194 A JP2000591194 A JP 2000591194A JP 2002533125 A5 JP2002533125 A5 JP 2002533125A5
Authority
JP
Japan
Prior art keywords
seq
construct
nucleotide sequence
sequence shown
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000591194A
Other languages
English (en)
Japanese (ja)
Other versions
JP4776075B2 (ja
JP2002533125A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/031272 external-priority patent/WO2000039303A2/en
Publication of JP2002533125A publication Critical patent/JP2002533125A/ja
Publication of JP2002533125A5 publication Critical patent/JP2002533125A5/ja
Application granted granted Critical
Publication of JP4776075B2 publication Critical patent/JP4776075B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000591194A 1998-12-31 1999-12-30 改変ｈｉｖｅｎｖポリペプチド Expired - Fee Related JP4776075B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11449598P 1998-12-31 1998-12-31
US60/114,495 1998-12-31
US15667099P 1999-09-29 1999-09-29
US60/156,670 1999-09-29
PCT/US1999/031272 WO2000039303A2 (en) 1998-12-31 1999-12-30 Modified hiv env polypeptides

Publications (3)

Publication Number Publication Date
JP2002533125A JP2002533125A (ja) 2002-10-08
JP2002533125A5 true JP2002533125A5 (https=) 2007-02-22
JP4776075B2 JP4776075B2 (ja) 2011-09-21

Family

ID=26812260

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000591194A Expired - Fee Related JP4776075B2 (ja) 1998-12-31 1999-12-30 改変ｈｉｖｅｎｖポリペプチド

Country Status (12)

Country Link
US (3) US6689879B2 (https=)
EP (1) EP1141315B1 (https=)
JP (1) JP4776075B2 (https=)
AT (1) ATE384795T1 (https=)
AU (1) AU2596600A (https=)
CA (1) CA2358915C (https=)
CY (1) CY1107393T1 (https=)
DE (1) DE69938062T2 (https=)
DK (1) DK1141315T3 (https=)
ES (1) ES2299276T3 (https=)
PT (1) PT1141315E (https=)
WO (1) WO2000039303A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
EP2280074A3 (en) * 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
EP1411770A4 (en) 2001-07-05 2006-05-10 Chiron Corp POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AU2003301556A1 (en) 2002-05-07 2004-05-13 Chiron Corporation Hiv envelope-cd4 complexes and hybrids
CA2501476A1 (en) 2002-10-07 2004-04-22 Chiron Corporation Hiv vaccine formulations
WO2005027840A2 (en) * 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
US7622125B2 (en) * 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
WO2006085959A2 (en) 2004-06-08 2006-08-17 Novartis Vaccines And Diagnostics Inc. Fusion proteins comprising cd4 minimal modules and methods of use thereof
EP2309269B1 (en) * 2004-09-08 2016-10-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Compositions and methods for the detection of HIV-1/HIV-2 infection.
CN101072585A (zh) 2004-11-01 2007-11-14 诺华疫苗和诊断公司 产生免疫应答的组合方法
ATE471947T1 (de) 2005-02-03 2010-07-15 Novartis Vaccines & Diagnostic Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CN101591379B (zh) * 2008-05-27 2017-01-18 中国疾病预防控制中心性病艾滋病预防控制中心 基于eiav减毒活疫苗的氨基酸突变而构建的抗hiv疫苗
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
CN104271155A (zh) 2011-11-14 2015-01-07 诺华股份有限公司 聚阴离子卡波姆和Env多肽的免疫原性复合物及其制造方法和用途
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
EP3380605A1 (en) 2015-11-24 2018-10-03 GlaxoSmithKline Intellectual Property Development Limited Transient transfection method for retroviral production
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US6858712B1 (en) * 1984-08-22 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Cloning and expression of HTLV-III DNA
US5032510A (en) 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
EP0203177A4 (en) 1984-11-29 1987-04-28 Scripps Clinic Res POLYPEPTIDES AND ANTIBODIES ASSOCIATED WITH VIRAL GLUCOPROTEINS WITHOUT GLUCOSE.
DE3588134T2 (de) 1984-12-24 1997-03-20 Genentech Inc Fusionen von AIDS-verwandten Polypeptiden
FI861626A7 (fi) * 1985-04-19 1986-10-20 Hoffmann La Roche Foervaervat immunbristsyndrom (aids) -relaterat viralt rekombinant hoeljeprotein samt ett testfoerfarande foer aids.
ATE108022T1 (de) 1985-10-24 1994-07-15 Southwest Found Biomed Res Synthetische peptide und deren verwendung zur diagnose und impfung für aids und arc.
EP0242216A1 (en) 1986-04-16 1987-10-21 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Non-cytopathic clone of Human T-Cell Lymphotropic Virus type III
JPH01500432A (ja) 1986-07-21 1989-02-16 サウスウェスト・ファウンデーション・フォー・バイオメディカル・リサーチ Ａｉｄｓおよびａｒｃのウィルス原因物質に対して免疫化するための組成物および方法
US4861707A (en) 1987-02-02 1989-08-29 E. I. Du Pont De Nemours And Company Human immunodeficiency virus antigen
US5256767A (en) 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
EP0300213A1 (en) 1987-06-22 1989-01-25 Hexal-Pharma Gentechnik GmbH & Co. KG Hepatitis a viral peptide particle immunogens
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
WO1989002277A2 (en) 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
JPH02501192A (ja) 1987-09-04 1990-04-26 バイオジェン インコーポレイテッド 可溶性ｔ４蛋白を製造するためのｄｎａ配列、組換ｄｎａ分子および方法
US5879907A (en) 1987-09-14 1999-03-09 Skandigen Ab Artificial gene coding for authentic human serum albumin, use thereof and method
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
IL87902A0 (en) 1987-10-08 1989-03-31 Dana Farber Cancer Inst Inc Soluble human cd4 fragments and applications thereof
US5683864A (en) 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5712088A (en) 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5714596A (en) 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
CA1340748C (en) 1988-07-13 1999-09-14 Stephen Oroszlan Synthetic hiv protease gene and method for its expression
ATE112687T1 (de) 1988-09-13 1994-10-15 Chiron Corp Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
AU640619B2 (en) 1988-10-03 1993-09-02 Repligen Corporation Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
CA2003383A1 (en) 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
IL93682A (en) 1989-03-16 1996-06-18 Yeda Res & Dev Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
WO1990011359A1 (en) 1989-03-20 1990-10-04 Whitehead Institute For Biomedical Research Intracellular method of inhibiting hiv in mammalian cells
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
AU5421090A (en) 1989-04-05 1990-11-05 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A clone of double-stranded rna virus and applications thereof
JP3034025B2 (ja) 1989-06-01 2000-04-17 アプライド・バイオテクノロジー・インコーポレーテツド 自己アセンブルド欠損非自己増殖性ウイルス粒子
US5130247A (en) 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAG
AU6523590A (en) 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
EP0424748B1 (en) 1989-10-23 1995-05-10 F. Hoffmann-La Roche Ag Synthetic envelope peptides of HTLV-I
WO1991006319A1 (en) 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
WO1991007510A1 (en) 1989-11-17 1991-05-30 Amgen Inc. A method of detecting htlv-i antibodies in human body fluids
EP0502105A4 (en) 1989-11-20 1993-02-24 Oncogen Limited Partnership Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
CA2077753C (en) 1990-03-09 2000-02-29 Nancy L. Haigwood Purified gp120 composition retaining natural conformation
US5876724A (en) 1990-03-19 1999-03-02 Institut Pasteur Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
ATE183235T1 (de) 1990-03-21 1999-08-15 Wolf Hans Joachim Prof Dr Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon
WO1991015512A2 (en) 1990-04-03 1991-10-17 Genentech, Inc. Hiv envelope polypeptides
JP3494300B2 (ja) 1990-04-03 2004-02-09 ジェネンテック・インコーポレーテッド Ｈｉｖに対する予防接種のための方法および組成物
IL97985A0 (en) 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
AP237A (en) 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
WO1991019803A1 (en) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
SE470074B (sv) 1990-08-16 1993-11-01 Replico Medical Ab Förfarande för diagnos av picorna- och/eller flavivirusinfektion, peptider, diagnostiska antigener och vaccinkomposition med dessa peptider
AU641554B2 (en) 1990-08-29 1993-09-23 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Novel peptide antigens and immunoassays, test kits and vaccines using the same
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
EP0550516A1 (en) 1990-09-28 1993-07-14 Hospital For Joint Diseases Method for inhibiting the infectivity of human immunodeficiency virus
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
PT100090A (pt) 1991-02-04 1993-07-30 Univ Saskatchewan Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
CA2104958A1 (en) 1991-03-07 1992-09-08 Jean C. Nichols Use of cell surface receptor targeted molecules for the treatment of viral diseases
WO1993002102A1 (en) 1991-07-23 1993-02-04 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Novel peptide antigens and immunoassays, test kits and vaccines using the same
WO1993004090A1 (en) 1991-08-22 1993-03-04 Nissin Shokuhin Kabushiki Kaisha Hiv immunotherapeutics
US5665569A (en) 1991-08-22 1997-09-09 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
RU2212899C2 (ru) 1991-09-13 2003-09-27 Чирон Корпорейшн Hcv иммунореактивные полипептидные композиции
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
CA2105629A1 (en) 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
US5686078A (en) 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
US5304472A (en) 1992-11-20 1994-04-19 Genentech, Inc. Method of controlling polypeptide production in bacterial cells
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
WO1994016081A1 (de) 1993-01-16 1994-07-21 Manfred Schawaller Verfahren zur gewinnung nativer domänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
KR100325554B1 (ko) 1993-03-26 2002-11-02 젠-프로브 인코포레이티드 사람의면역결핍 바이러스타입1의검출
US5869624A (en) * 1993-03-26 1999-02-09 Progenics Pharmaceuticals, Inc. HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
WO1994028929A1 (en) * 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides
CN1111540C (zh) 1993-06-09 2003-06-18 康诺特实验室有限公司 串联的合成hiv－1肽类
US5614413A (en) 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
US6291157B1 (en) 1998-02-23 2001-09-18 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
US5955342A (en) 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5550280A (en) 1994-11-30 1996-08-27 Uniroyal Chemical Ltd./ Uniroyal Chemical Ltee Hindered aromatic ester compounds useful as anti-viral agents
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US5741492A (en) 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6087486A (en) 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein
US6060587A (en) 1996-01-29 2000-05-09 The Trustees Of The University Of Pennsylvania Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
US5951975A (en) 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
WO1998010069A2 (en) 1996-09-06 1998-03-12 The Regents Of The University Of California E25a PROTEIN, METHODS FOR PRODUCTION AND USE THEREOF
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6139833A (en) 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
US5858675A (en) 1997-05-13 1999-01-12 Incyte Pharmaceuticals, Inc. Double-stranded RNA-binding protein
US6099847A (en) 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
US5932442A (en) 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
WO1999053046A2 (en) 1998-04-14 1999-10-21 Chiron Corporation Noncloning technique for expressing a gene of interest
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
US6316253B1 (en) 1999-11-01 2001-11-13 Chiron Corporation Expression vectors, transfection systems, and method of use thereof

Similar Documents

Publication Publication Date Title
JP2002533125A5 (https=)
JP2004533208A5 (https=)
JP2002542827A5 (https=)
JP2001081042A5 (https=)
RU2004134341A (ru) Экспрессирующая система
JP2003523721A5 (https=)
CA2358915A1 (en) Modified hiv env polypeptides
RU2003103779A (ru) Экспрессионная система
JP2019519252A5 (https=)
WO2003038057A3 (en) Genetic vaccine against human immunodeficiency virus
JP2010500399A5 (https=)
JP2004508808A5 (https=)
JP2006149406A5 (https=)
AR050102A1 (es) Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida
GR3023717T3 (en) Process for recovering native domains of viral membrane proteins, their use, in particular as vaccine against hiv.
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
EP2011510A3 (en) Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
JP2003510050A5 (https=)
JPH10262686A5 (https=)
JP2004509601A5 (https=)
JPH11332586A5 (https=)
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
AU697040B2 (en) Retrovirus from the HIV group and its use
WO2003090667A3 (fr) Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16
WO2003097673B1 (en) Chimeric human papillomavirus 16 l1 proteins comprising an l2 peptide,virus-like particles prepared therefrom and a method for preparing the particles.